News from MRC/UVRI and LSHTM Uganda Research Unit

Featured
PrEPVacc meets the media in Masaka
PrEPVacc meets the media in Masaka
FAQs for PrEPVacc's vaccine result
FAQs for PrEPVacc's vaccine result
Media coverage of PrEPVacc's July 2024 vaccine result announcement
Media coverage of PrEPVacc's July 2024 vaccine result announcement
News Release: HIV vaccines tested in PrEPVacc fail to reduce infections
News Release: HIV vaccines tested in PrEPVacc fail to reduce infections
AIDS 2024: “I am not sick, why should I swallow daily pills?”: non-uptake of, and adherence to daily oral pre-exposure prophylaxis among adults at high-risk of HIV in Masaka, Uganda
AIDS 2024: “I am not sick, why should I swallow daily pills?”: non-uptake of, and adherence to daily oral pre-exposure prophylaxis among adults at high-risk of HIV in Masaka, Uganda
AIDS 2024: Knowledge and experiences of participating in an HIV vaccine efficacy trial with second randomization to oral pre-exposure prophylaxis in South Africa, Tanzania, and Uganda
AIDS 2024: Knowledge and experiences of participating in an HIV vaccine efficacy trial with second randomization to oral pre-exposure prophylaxis in South Africa, Tanzania, and Uganda
AIDS 2024: Disclosing of Participation in an HIV Vaccine Trial in Southwestern Uganda – the effect on participant engagement
AIDS 2024: Disclosing of Participation in an HIV Vaccine Trial in Southwestern Uganda – the effect on participant engagement
AVAC briefing on PrEPVacc: An in-depth look at the trial, and what’s next
AVAC briefing on PrEPVacc: An in-depth look at the trial, and what’s next
News Release: Experimental HIV vaccine regimens likely to be ineffective in preventing HIV acquisition, PrEPVacc study reports
News Release: Experimental HIV vaccine regimens likely to be ineffective in preventing HIV acquisition, PrEPVacc study reports
STAT: 'Can the world still invent an HIV vaccine? Progress in one area creates new problem'
STAT: 'Can the world still invent an HIV vaccine? Progress in one area creates new problem'
CNN reports on ‘the last roll of the dice’ for an HIV vaccine this decade
CNN reports on ‘the last roll of the dice’ for an HIV vaccine this decade
News Release: African-led PrEPVacc HIV prevention study completes its enrolment
News Release: African-led PrEPVacc HIV prevention study completes its enrolment
Video to help inform PrEPVacc participants posted online
Video to help inform PrEPVacc participants posted online
Attitudes towards PrEP uptake and adherence explored in Masaka, Uganda
Attitudes towards PrEP uptake and adherence explored in Masaka, Uganda
Getty photographer visits PrEPVacc site at Masaka
Getty photographer visits PrEPVacc site at Masaka
PrEPVacc featured in December 2021 'Science et Vie' magazine cover story
PrEPVacc featured in December 2021 'Science et Vie' magazine cover story
‘African scientists should lead in developing an Aids jab for Africa’
‘African scientists should lead in developing an Aids jab for Africa’
PrEPVacc featured in JIAS articles in Nov 2021
PrEPVacc featured in JIAS articles in Nov 2021
Study leaders congratulate PrEPVacc teams on opening all trial sites
Study leaders congratulate PrEPVacc teams on opening all trial sites
Activists push for continuity of HIV vaccine research
Activists push for continuity of HIV vaccine research
Mbeya begins enrolment to PrEPVacc clinical trial
Mbeya begins enrolment to PrEPVacc clinical trial
HIV R4P Virtual: Community engagement and volunteer recruitment experiences in a HIV vaccine preparedness study in Masaka, Uganda
HIV R4P Virtual: Community engagement and volunteer recruitment experiences in a HIV vaccine preparedness study in Masaka, Uganda
HIV R4P Virtual: Changes in risky sexual behaviour among adult men and women in an HIV vaccine preparedness study in south-western Uganda
HIV R4P Virtual: Changes in risky sexual behaviour among adult men and women in an HIV vaccine preparedness study in south-western Uganda
HIV R4P Virtual: Recruitment of participants into an HIV vaccine preparedness study: Experiences from Masaka, Uganda
HIV R4P Virtual: Recruitment of participants into an HIV vaccine preparedness study: Experiences from Masaka, Uganda
‘Uganda volunteers in phase III of HIV vaccine efficacy trials’ - The East African reports on start of PrEPVacc
‘Uganda volunteers in phase III of HIV vaccine efficacy trials’ - The East African reports on start of PrEPVacc
PrEPVacc features in BBC’s 'Focus on Africa'
PrEPVacc features in BBC’s 'Focus on Africa'
NTV reports on PrEPVacc's first enrolments
NTV reports on PrEPVacc's first enrolments
First enrolments to PrEPVacc clinical trial at Masaka
First enrolments to PrEPVacc clinical trial at Masaka
PrEPVacc leaders contribute to future design of HIV prevention trials
PrEPVacc leaders contribute to future design of HIV prevention trials
First PrEPVacc SIV held at Masaka site
First PrEPVacc SIV held at Masaka site